Skip to main
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is well-positioned for success with its promising product pipeline and strategic plans for advancing their oral treatment options for underserved medical conditions. With next-generation EB613 slated to enter late-phase trials in 2026 and a strong leadership team, the company is on track to meet its goal of FDA approval in 2029. Furthermore, the recent equity financing has extended the company's runway, providing them with the necessary resources to move forward with their pivotal program and potentially reach commercialization.

Bears say

Entera Bio is currently facing a significant hurdle in obtaining FDA approval for its lead product candidate, EB613, as the company has yet to receive feedback from the FDA on its Phase 3 protocol and statistical analysis plan. Given the company's reliance on the combination of its oral peptide platform and a well-established drug for its indication, a favorable response from the FDA is crucial for the company's success. It is also worth noting that the company has no current product revenue and any further delays in obtaining FDA approval could potentially harm its financials.

ENTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, ENTX has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.